These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31608328)

  • 41. A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model.
    Kim JW; Miska J; Young JS; Rashidi A; Kane JR; Panek WK; Kanojia D; Han Y; Balyasnikova IV; Lesniak MS
    Mol Ther Oncolytics; 2017 Jun; 5():97-104. PubMed ID: 28573184
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model.
    Belcaid Z; Phallen JA; Zeng J; See AP; Mathios D; Gottschalk C; Nicholas S; Kellett M; Ruzevick J; Jackson C; Albesiano E; Durham NM; Ye X; Tran PT; Tyler B; Wong JW; Brem H; Pardoll DM; Drake CG; Lim M
    PLoS One; 2014; 9(7):e101764. PubMed ID: 25013914
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
    Gomez-Manzano C; Alonso MM; Yung WK; McCormick F; Curiel DT; Lang FF; Jiang H; Bekele BN; Zhou X; Alemany R; Fueyo J
    Clin Cancer Res; 2006 Jan; 12(2):556-62. PubMed ID: 16428500
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells.
    Tuyaerts S; Van Meirvenne S; Bonehill A; Heirman C; Corthals J; Waldmann H; Breckpot K; Thielemans K; Aerts JL
    J Leukoc Biol; 2007 Jul; 82(1):93-105. PubMed ID: 17449724
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression.
    Ghulam Muhammad AK; Candolfi M; King GD; Yagiz K; Foulad D; Mineharu Y; Kroeger KM; Treuer KA; Nichols WS; Sanderson NS; Yang J; Khayznikov M; Van Rooijen N; Lowenstein PR; Castro MG
    Clin Cancer Res; 2009 Oct; 15(19):6113-27. PubMed ID: 19789315
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
    Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
    Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenovirus-based strategies overcome temozolomide resistance by silencing the O6-methylguanine-DNA methyltransferase promoter.
    Alonso MM; Gomez-Manzano C; Bekele BN; Yung WK; Fueyo J
    Cancer Res; 2007 Dec; 67(24):11499-504. PubMed ID: 18089777
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.
    Dai B; Roife D; Kang Y; Gumin J; Rios Perez MV; Li X; Pratt M; Brekken RA; Fueyo-Margareto J; Lang FF; Fleming JB
    Mol Cancer Ther; 2017 Apr; 16(4):662-670. PubMed ID: 28138026
    [TBL] [Abstract][Full Text] [Related]  

  • 50. YB-1 dependent oncolytic adenovirus efficiently inhibits tumor growth of glioma cancer stem like cells.
    Mantwill K; Naumann U; Seznec J; Girbinger V; Lage H; Surowiak P; Beier D; Mittelbronn M; Schlegel J; Holm PS
    J Transl Med; 2013 Sep; 11():216. PubMed ID: 24044901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gospel of malignant Glioma: Oncolytic virus therapy.
    Li J; Meng Q; Zhou X; Zhao H; Wang K; Niu H; Wang Y
    Gene; 2022 Apr; 818():146217. PubMed ID: 35093451
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Delta-24 adenoviral therapy for glioblastoma: evolution from the bench to bedside and future considerations.
    Ene CI; Fueyo J; Lang FF
    Neurosurg Focus; 2021 Feb; 50(2):E6. PubMed ID: 33524949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.
    Balvers RK; Belcaid Z; van den Hengel SK; Kloezeman J; de Vrij J; Wakimoto H; Hoeben RC; Debets R; Leenstra S; Dirven C; Lamfers ML
    Viruses; 2014 Aug; 6(8):3080-96. PubMed ID: 25118638
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
    Wu J; Waxman DJ
    Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
    Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
    Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.
    Kiyokawa J; Wakimoto H
    Oncolytic Virother; 2019; 8():27-37. PubMed ID: 31750274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intratumor injection of oncolytic adenovirus expressing HSP70 prolonged survival in melanoma B16 bearing mice by enhanced immune response.
    Ren Z; Ye X; Fang C; Lu Q; Zhao Y; Liu F; Liang M; Hu F; Chen HZ
    Cancer Biol Ther; 2008 Feb; 7(2):191-95. PubMed ID: 18073525
    [TBL] [Abstract][Full Text] [Related]  

  • 58. YB-1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma.
    Holzmüller R; Mantwill K; Haczek C; Rognoni E; Anton M; Kasajima A; Weichert W; Treue D; Lage H; Schuster T; Schlegel J; Gänsbacher B; Holm PS
    Int J Cancer; 2011 Sep; 129(5):1265-76. PubMed ID: 21710499
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01.
    Vera B; Martínez-Vélez N; Xipell E; Acanda de la Rocha A; Patiño-García A; Saez-Castresana J; Gonzalez-Huarriz M; Cascallo M; Alemany R; Alonso MM
    PLoS One; 2016; 11(1):e0147211. PubMed ID: 26808201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.